Article Text

Download PDFPDF

751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor
  1. David Sommerhalder1,
  2. Marcus Noel2,
  3. Scott Boiko3,
  4. Scott Daigle3,
  5. Xinyan Zhang3,
  6. Patricia Fraser3,
  7. Amanda Hoerres3,
  8. Nawaid Rana3,
  9. Esha A Gangolli3,
  10. Frank G Basile4,
  11. Bhaskar Srivastava3,
  12. Sunil Sharma5,
  13. Rama Balaraman6 and
  14. Martin Gutierrez7
  1. 1NEXT Oncology, SAN ANTONIO, TX, USA
  2. 2Medstar Georgetown University Hospital, Washington, WA, USA
  3. 3Nimbus Therapeutics, Boston, MA, USA
  4. 4Nimbus, Kingston, MA, USA
  5. 5Translational Genomics Research Institute, Phoenix, AZ, USA
  6. 6Florida Cancer Affiliates-US Oncology, Ocala, FL, USA
  7. 7Hackensack University Medical Center, Hackensack, NJ, USA
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background NDI-101150 is a novel, oral, highly selective small molecule inhibitor of HPK1, a MAP4K family kinase that negatively regulates T cells, B cells, and dendritic cells. HPK1 inhibition is postulated to enhance immune responses and exert anti-tumor activity as a single agent and in combination with immune checkpoint therapies.1

Methods NDI-101150 is being studied in a dose escalation and expansion study as monotherapy and in combination with pembrolizumab. Monotherapy data are presented here. Increasing doses of NDI-101150 were administered once daily to patients with relapsed and metastatic solid tumors following a 3+3 cohort design. Primary objectives include determination of recommended phase 2 dose(s) and maximum tolerated dose. Secondary objectives include characterization of safety, pharmacokinetic (PK) profiles, and preliminary antitumor activity. Exploratory analyses include evaluating proximal pharmacodynamic (PD) target engagement of HPK1 by measuring phosphorylated SLP76 (pSLP76).

Results As of 17 May 2023, 22 subjects have been studied at 4 dose levels. Eighteen subjects (81.8%) experienced at least 1 treatment related adverse event (TRAE). Three subjects (13.6%) experienced serious TRAEs. The most common TRAEs were vomiting, nausea, diarrhea, and fatigue, with the majority being Grade 1 or 2. Immune-related adverse events occurred in 4 subjects (18.2%). There were no treatment-related deaths. Dose level 4 was considered a non-tolerated dose, with 2 out of 6 patients experiencing the only dose-limiting toxicities observed (Grade 3 pneumonitis and Grade 3 acute kidney injury in the setting of vomiting and diarrhea; both serious TRAEs). Nearly dose proportional increase in Cmax/AUC was observed. PD results demonstrated >50% reduction of pSLP76 in each cohort by Cycle 1 Day 15 (figure 1). One patient with renal cell carcinoma (RCC) in cohort 1 experienced a complete response and remained on treatment for 9 months. Two additional patients (RCC and pancreatic cancer in cohorts 3 and 4) have experienced prolonged stable disease with evidence of tumor shrinkage and response in CA 19.9 respectively. They remain on treatment at 13 months and 9 months, respectively (figure 2). Monotherapy dose optimization as well as combination dose escalation are ongoing.

Conclusions Preliminary results from the NDI-101150 monotherapy dose escalation demonstrate an acceptable safety profile, proximal target engagement and evidence of single agent activity with this novel class of oral immunotherapy in patients with relapsed and metastatic solid tumors. Updated clinical, PK and PD data will be presented.

Trial Registration NCT05128487


  1. 1. Sawasdikosol S, Burakoff S. A perspective on HPK1 as a novel immuno-oncology drug target. Elife. 2020 Sep 8;9:e55122.

Ethics Approval This trial was approved by the institutional review board and/or ethics committee as required for each participating site (IRB name and approval number for each site is available per request).

Abstract 751 Figure 1

Reduction of pSLP76 by cohort following NDI-101150 treatment. Inhibition of HPK1 activity by NDI-101150 is measured by quantifying the median fluorescence intensity of CD8+ T-cells in peripheral blood stimulated ex-vivo. Data are represented as the mean +/- standard error of mean of subjects analyzed in each cohort.

Abstract 751 Figure 2

Swimmer plot of responses based on RECIST 1.1

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.